1/42
Looks like no tags are added yet.
Tumor Immunity Cycle
Tumor antigens are released
APC activation
T-cell Priming
T-cell trafficking
Tumor Infiltration
Tumor recognition
Tumor Killing
Immunotherapies can impact each one of these steps
IFN Gamma Normal Actions
Activates macrophages so they can kill microbes
Increases MHC I and MHC II expression to help APCs present antigens to T-cells
Promotes Th1 response
Supports antitumor activity by helping immune cells recognize and attack tumor cells
TGF-Beta Normal Actions
Suppresses immune responses and regulates tissues
Suppresses T cell activity limiting excessive immune response
Promotes regulatory T-cell development preventing autoimmunity
Inhibits certain immune cell functions, reducing inflammation
Promotes tissue repair and fibrosis, depending on the tissue and context
What is required for tumor elimintation
Antigen recognition
T-cell activation
Tumor infiltration
Tumor killing
Tumors can escape by disrupting one or more of these steps
Hot Tumors
Characterized by High CD8 T cell infiltration, High IFN-gamma, Often PD-L1 positive.
Examples of Hot tumors
Melanoma
Hodkin Lymphoma
MSI-high tumors
Cold Tumors
Characterized by few T cells, poor antigenicity, little inflammation.
Examples of cold tumors
Pancreatic cancer
Some prostate cancers
Immune excluded characteristics
T cells are present but the T cells can not enter the tumor
Often associated with TGF-Beta, stromal barriers, and VEGF
Tumor Infiltrating Lymphocytes
In a hot Tumor there are many CD8 cells
In a cold tumor there are few CD8 cells
Likely strategy to combat the different tumor phenotypes
Hot: PD-1 Inhibitor
Cold: Recruitment strategy
Excluded: TME-targeted therapy
What are the 3 major tumor escape mechanisms
Hide from immune recognition
Suppress T-Cell activation
Build an immunosuppressive microenvironment
How do tumors hide from immune recognition
Antigen loss, MHC-1 loss, Defective antigen presentation
Makes it so the T cells cannot recognize the tumor
How do tumors Suppress T-cell activation
They exploit CTLA-4s checkpoint inhibition of T-cells
(CTLA4 (receptor) inhibits CD80 from binding to CD28 which prevents co-stimulation)
They also exploit the PD-1/PD-L1 Checkpoint pathway
(Binding PD to PD-L1 inhibits T cell function)
Consequences of PD-L1 Activation
Reduced Cytokine production
Reduced cytotoxicity
T-cell exhaustion
PD-1 Checkpoint inhibitors
Restore Effector Function and Cytotoxic activity
CAR T Cell Therapy
Chimeric Antigen Receptor T Cell Therapy
Alters the genes in a person’s T cells to help attack cancer. T cells can be taken from patient’s blood and genetically changes in the ab to have a chimeric antigen receptor on its outer surface. These receptors help T cells attach to a specific cancer antigen. The CAR T cells are then returned to patient’s blood.
Kind of Checkpoint inhibitors
PD-1 Inhibitors (Pembrolizumab, Nivolumab)
PD-L1 Inhibitors (Atezolizumab, Durvalumab)
CTLA-4 Inhibitors (Ipilimumab)
Examples of Tumor Suppressive Soluble Mediators
TGF-B
IL-10
Adenosine
VEGF
Emerging tumor therapeutics
Other checkpoints like LAG-3, TIGIT, TIM-3
Microenvironment modifiers
Bispecific antibodies
Major Suppressive Components of Tumor Environment
Tregs
MDSCs
M2 Macrophages
How do tumors form immunosuppressive environments
Heterogeneity of constitution
Lack of Tumor Antigen
Defect of Antigen presenting
Impairment of T-cell infiltration
Activation of immunosuppressive metabolism
Heterogeneity of constitution
Tumor cells are genetically and biologically diverse. Some tumor cells may be less recognizable to the immune system or more resistant to immune attack
Lack of antigen tumor
Tumor cells may not express enough recognizable antigens, or they may lose antigens making them harder for T cells to identify
Defects of antigen presenting
Tumor antigens may not be processed or presented effectively, limiting T-cell recognition and activation
Impairment of T-cell infiltration
T cells cannot efficiently enter or move through the tumor tissue to reach cancer cells
Activation of immunosuppressive signaling pathways
Tumors activate inhibitory mechanisms such as PD-1/PD-L1 signaling and can use cytokines such as TGF-B to suppress immune responses
Enhancement of immunosuppressive metabolism
Tumors alter nutrient availability and produce metabolites that impair T-cell function.
Cytokines modulating therapies
Enhance immune activation and expansion
IL-2 based therapies
IFN based approaches
Engineered cytokines
Emerging Biologics
TGF-Beta inhibitors
CSF1R inhibitors
Adenosine pathway inhibitors
Bispecific antibodies
Combination Immunotherapy
CTLA-4 blockade + PD-1 blockade. Targets both T-cell priming and T-cell activation. Tumors frequently employ multiple escape mechanisms simultaneously, need to administer multiple drugs to target the different pathways.
Kinds of combination therapy
Simultaneous attack - using two or more drugs at the same time to hit different pathways
Sequential attack - using drugs in a specific order one after another to overcome resistance.
Acquired Resistance
Sometimes tumors relapse after immunotherapy.
Potential mechanisms of acquired resistance
Antigen loss
MHC downregulation
Alternative checkpoints (LAG-3, TIGIT)
Immunosuppressive microenvironment adaptation
What makes a good Biomarkers
It should indicate if an immune response is present, why might block it, and if that block can be reversed
Interpreting high IFN gamma
there is an existing antitumor immune response
Interpreting CXCL9/CXCL10
Active T-cell recruitment is occurring
Interpreting high TGF-B
Immune exclusion is occurring
Interpreting high IL-10
There is a suppressive immunoenvironment
What can biomarkers be used for
Screening, prognosis, diagnosis, staging, risk assessment, stratification, monitoring, therapy planning
Why do biomarkers sometimes fail
They can help inform decisions but rarely determine them completely.
PD-L1 expression is dynamic
Different assays produce different scores
Tumors are heterogneous
High PD-l1 does not guarantee a response and low PD-L1 does not guarantee failure
The immunology decision Tree
Is there an immune response
What is preventing tumor elimination
Which pathway can be targeted
Which biomarker supports that choice
Select mechanism-based therapy